Supply Chain Intelligence

Upstream Bio, Inc. Supply Chain

UPB supply chain intelligence for Upstream Bio, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

UPB ·Last updated 2026-07-30 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

4Suppliers
3Customers
2Debt Items
20Related Chains

Upstream Bio, Inc. Suppliers

TickerNameConfidenceEvidence
AZN AstraZeneca PLC 72% ise such that they may be more successful than us in obtaining regulatory approval and achieving widespread market acceptance. • We expect to expand our organization, and as a result, we may encounte…
AZN AstraZeneca PLC 72% Reciprocal relationship from AZN graph: Reciprocal relationship from UPB graph: Reciprocal relationship from AZN graph: Reciprocal relationship from UPB graph: Reciprocal relationship from AZN graph:…
SNYNF Sanofi 72% or development of AI technologies. In addition, various federal regulators have issued guidance and focused enforcement efforts on the use of AI in regulated sectors. The FDA, for example, issued dra…
SNYNF Sanofi 72% Reciprocal relationship from SNYNF graph: Reciprocal relationship from UPB graph: or development of AI technologies. In addition, various federal regulators have issued guidance and focused enforceme…

Upstream Bio, Inc. Customers

TickerNameConfidenceEvidence
MARUHO MARUHO 90% The Company concluded that Maruho is a customer under the Maruho Agreement, and as such, the Maruho Agreement falls within the scope of ASC 606
SNYNF Sanofi 72% or development of AI technologies. In addition, various federal regulators have issued guidance and focused enforcement efforts on the use of AI in regulated sectors. The FDA, for example, issued dra…
SNYNF Sanofi 72% Reciprocal relationship from SNYNF graph: Reciprocal relationship from UPB graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from UPB graph: Reciprocal relationship from SNYNF …

Upstream Bio, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
UPB-DEBT Debt stack $1.1M 90% Market cache reports total debt of $1.1M.
UPB-DEBT-13229 Xbrl Convertible 90% xbrl convertible detail from xbrl 2024-09-30.

Upstream Bio, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Upstream Bio, Inc..

Upstream Bio, Inc. Ownership

HolderNameConfidenceEvidence
UPB-OWNER-FMR-LLC FMR LLC 90% 13F overlay lists FMR LLC as top holder; 144 tracked holders.

Upstream Bio, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
CHRS Coherus Oncology, Inc. 100.00 2
EDIT Editas Medicine, Inc. 100.00 2
EDSA Edesa Biotech, Inc. 100.00 2
BLRX BioLineRx Ltd. 100.00 2
ANL Adlai Nortye Ltd. 100.00 2
DBVTF DBV TECHNOLOGIES 100.00 2
WHWK Whitehawk Therapeutics, Inc. 100.00 2
BNBX BNB Plus Corp. 100.00 2
CTMX CytomX Therapeutics, Inc. 100.00 2
BIOA BioAge Labs, Inc. 100.00 2
CYTK Cytokinetics, Incorporated 100.00 2
CBIO Crescent Biopharma, Inc. 100.00 2
ANRO Alto Neuroscience, Inc. 100.00 2
ALXO ALX Oncology Holdings Inc. 100.00 2
CYTOF Altamira Therapeutics Ltd. 100.00 2
CCEP Coca-Cola Europacific Partners PLC 100.00 2
DSGN Design Therapeutics, Inc. 100.00 2
PSNL Personalis, Inc. 100.00 2
AZN AstraZeneca PLC 100.00 2 ['supplier']
ATOS Atossa Therapeutics, Inc. 100.00 2
View UPB supply chain intel →

Explore the full interactive supply chain map for Upstream Bio, Inc..

Open UPB supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map